Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity

Cancer Research

Volumn 71, Issue 20, 2011, Pages 6514-6523

  Lee, Seok Geun ^a   Kim, Keetae ^c   Kegelman, Timothy P ^c   Dash, Rupesh ^c   Das, Swadesh K ^c   Choi, Jung Kyoung ^a   Emdad, Luni ^c   Howlett, Eric L ^c,d   Jeon, Hyun Yong ^c   Su, Zhao Zhong ^c   Yoo, Byoung Kwon ^c   Sarkar, Devanand ^c,d   Kim, Sung Hoon ^a   Kang, Dong Chul ^b   Fisher, Paul B ^c,d  

^a Kyung Hee University   (South Korea)

^b Hallym University   (South Korea)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NERVE GROWTH FACTOR; NEURON SPECIFIC NUCLEAR PROTEIN; TRANSCRIPTION FACTOR YY1;

AEG 1 GENE; ARTICLE; BINDING SITE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; EAAT2 GENE; EXCITOTOXICITY; GAIN OF FUNCTION MUTATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; NERVE DEGENERATION; ONCOGENE; PATHOGENESIS; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TUMOR GROWTH;

ANIMALS; ASTROCYTES; BRAIN; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CREB-BINDING PROTEIN; GLIOMA; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; HUMANS; NERVE DEGENERATION; ONCOGENES; PROMOTER REGIONS, GENETIC; RATS; YY1 TRANSCRIPTION FACTOR;

EID: 80054024743     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0782     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23. (Pubitemid 32052502)
3. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007;64:458-78.
4. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25; discussion 26-9.
5. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501. (Pubitemid 37328837)
6. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 2002;58:1759-64. (Pubitemid 34663574)
7. Hofer S, Herrmann R. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J Cancer Res Clin Oncol 2001;127:91-5.
8. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 2001;56:118-20. (Pubitemid 32059666)
9. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33. (Pubitemid 32524640)
10. Rothstein JD. Paving new pathways. Nat Med 2002;8:938-40. (Pubitemid 35033690)
11. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008;105:287-95. (Pubitemid 351490026)
12. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 2000;32:1-14.
13. Headley PM, Grillner S. Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sci 1990;11:205-11. (Pubitemid 20139306)
14. Bunch L, Erichsen MN, Jensen AA. Excitatory amino acid transporters as potential drug targets. Expert Opin Ther Targets 2009;13:719-31.
15. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics. J Cell Physiol 2011;226:2484-93.
16. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7. (Pubitemid 40101145)
17. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383-91. (Pubitemid 29418758)
18. Ye ZC, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 1999;19:10767-77. (Pubitemid 30235723)
19. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 2010;97:11-23.
20. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001;7:1010-5. (Pubitemid 32937380)
21. Sarkar D, Emdad L, Lee SG, Yoo BK, Su ZZ, Fisher PB. Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes. Cancer Res 2009;69:8529-35.
22. Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002;21:3592-602. (Pubitemid 34587691)
23. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A 2006;103:17390-5. (Pubitemid 44788979)
24. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2008;27:1114-21. (Pubitemid 351253177)
25. Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB. Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res 2008;68:1478-84. (Pubitemid 351346856)
26. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, et al. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci U S A 2009;106:21300-5.
27. Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res 2010;70:3249-58.
28. Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK, Dash R, et al. Astrocyte elevated gene-1: a novel target for human glioma therapy. Mol Cancer Ther 2010;9:79-88.
29. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009;119:465-77.
30. Lee SG, Jeon HY, Su ZZ, Richards JE, Vozhilla N, Sarkar D, et al. Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene 2009;28:2476-84.
31. Liu L, Wu J, Ying Z, Chen B, Han A, Liang Y, et al. Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 2010;70:3750-9.
32. Xia Z, Zhang N, Jin H, Yu Z, Xu G, Huang Z. Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas. Clin Neurol Neurosurg 2010;112:413-9.
33. Su ZZ, Chen Y, Kang DC, Chao W, Simm M, Volsky DJ, et al. Customized rapid subtraction hybridization (RaSH) gene microarrays identify overlapping expression changes in human fetal astrocytes resulting from human immunodeficiency virus-1 infection or tumor necrosis factor-alpha treatment. Gene 2003;306:67-78. (Pubitemid 36351396)
34. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 2005;353:8-15. (Pubitemid 40805356)
35. Su ZZ, Leszczyniecka M, Kang DC, Sarkar D, Chao W, Volsky DJ, et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci U S A 2003;100:1955-60. (Pubitemid 36254555)
36. Wang Z, Trillo-Pazos G, Kim SY, Canki M, Morgello S, Sharer LR, et al. Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol 2004;10 Suppl 1:25-32. (Pubitemid 38325090)
37. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 2005;65:1934-40. (Pubitemid 40478623)
38. Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008;283:13116-23.
39. Wang CC, Chen JJ, Yang PC. Multifunctional transcription factor YY1: a therapeutic target in human cancer? Expert Opin Ther Targets 2006;10:253-66.
40. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009;27:693-733.
41. Thirkettle HJ, Girling J, Warren AY, Mills IG, Sahadevan K, Leung H, et al. LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res 2009;15:3003-13.
42. Sitcheran R, Gupta P, Fisher PB, Baldwin AS. Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNF-alpha-controlled repression. EMBO J 2005;24:510-20. (Pubitemid 40343253)
43. Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42:869-73.